HitGen(SH:688222)2024-02-22 09:06Group 1: Company Overview - Chengdu XianDao focuses on becoming a world-class innovative biopharmaceutical company, contributing to human health [3] - The company specializes in small molecule and nucleic acid drug discovery and optimization, leveraging four core technology platforms [3][4] - Established in 2012, Chengdu XianDao has expanded its operations globally, with subsidiaries in the UK and the US [4] Group 2: Technology Platforms - The DNA-encoded compound library (DEL) has over 1.2 trillion molecules, with more than 6,000 types of synthetic scaffolds [4][11] - The company has multiple internal drug projects at various clinical and preclinical stages [4] - FBDD/SBDD technology is crucial for small molecule drug discovery, with successful drugs already on the market [5][6] Group 3: Drug Development and Services - Chengdu XianDao has developed a comprehensive platform for oligonucleotide drug development, covering early research to commercialization [8][9] - The company’s subsidiary, Sichuan XianDong Pharmaceutical, provides CDMO services for small nucleic acid drugs, meeting clinical trial needs [9][10] - The company has completed over 700 compound IP transfers, with 85% of transferred compounds featuring novel molecular scaffolds [12] Group 4: Competitive Advantages - The integration of DEL and AI technologies enhances compound screening efficiency and expands the chemical space for drug discovery [10][11] - Chengdu XianDao's DEL library is the largest known small molecule compound library, with over 12 trillion subtypes [11] - The company has achieved a success rate of over 70% in obtaining functional molecules across hundreds of targets [11] Group 5: Focus on IL-17A - Chengdu XianDao is one of the first companies in China to develop oral small molecule inhibitors for IL-17A, targeting inflammatory diseases [13] - The company is optimizing its second-generation IL-17A small molecule product pipeline [13]